Hormone replacement therapy for women after breast carcinoma

Current Opinion in Obstetrics and Gynecology

Volumn 8, Issue 3, 1996, Pages 216-220

  Sands, Robert ^a   Studd, John ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLONIDINE; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; PREMPAK; PROPRANOLOL; TAMOXIFEN;

BREAST CARCINOMA; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; ESTROGEN DEFICIENCY; FEMALE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; META ANALYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW;

EID: 0029992736     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-199606000-00012     Document Type: Review

References (41)

1. Olivotto JA, Bajdik CD, Math M, Plenderleith IH, Coppin CM, Gelmon KA, Jackson SM, Ragaz J, Wilson KS, Worth A: Adjuvant systemic therapy and survival after breast cancer. N Engl J Med 1994, 330:805-809.
2. Cobleigh MA, Berris RF, Bush T, Davidson NE, Robert NJ, Sparano JA, •• Tormey DC, Wood WC: Estrogen replacement in breast cancer survivors. JAMA 1994, 272:540-545. An excellent and methodical reassessment of all the health issues of menopausal women with a history of breast cancer. This paper will serve as a comprehensive review of the literature on this subject.
3. Gail MH, Benichou J: Assessing the risk of breast cancer in individuals. Cancer Prev 1992, 1:1-15.
4. Adami HO, Holmberg L, Malker B: Survival and age at diagnosis in breast cancer [Letter]. N Engl J Med 1987, 316:752.
5. Sacks NM: How much of the effect of chemotherapy is due to hormonal manipulation? Controversial Issues in the Management of Apparently Non-Disseminated Breast Cancer. Edited by Fletcher GH, Levitt SH. New York: Springer-Verlag; 1993:25-27.
6. Bulun SE, Price TM, Aitken J: A link between breast cancer and local oestrogen biosynthesis suggested by quantification of breast at opposed tissue aromatase cytochrome P 450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 1992, 77:1622-1628.
7. Miller WR, Mullen P: Factors influencing aromatase activity in the breast. J Steroid Biochem Mol Biol 1993, 44:597-604.
8. Armstrong BK: Oestrogen therapy after the menopause-boon or bane? Med J Austral 1988, 148:213-214.
9. Dupont WD, Page DL: Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991, 151:67-72.
10. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, Berkelman RL: A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991, 265:1985-1990.
11. Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R: Menopausal hormone replacement therapy and breast cancer; a meta-analysis. Obstet Gynecol 1992, 79:286-294.
12. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings S: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992, 117:1016-1037.
13. Colditz GA, Egan KM, Stampfer MJ: Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993, 168:1473-1480.
14. Steinberg KK, Smith SJ, Thacker SB, Stroup DF: Breast cancer risk and duration of estrogen use: the role of study design in metaanalysis. Epidemiology 1994, 5:415-421.
15. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN: Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 1994, 5:491-500.
16. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, • Stampher ME, Hennekens C, Rosner B, Speizer FE: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995, 332:1589-1593. This paper is a further follow-up of the Nurses Health Study. The conclusion that breast cancer death and incidence is increased with long-term use in E/ HRT users compared with non-users is a sobering reminder of the lack of consensus of the data.
17. La Vecchia C, Negri E, Franceschi S, Favero A, Nanni O, Filiberti R, Conti E, Montella M, Veronosi A, Ferraroni M, Decarli A: Hormone replacement treatment and breast cancer risk: a cooperative Italian study. Br J Cancer 1995, 72:244-248.
18. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA: Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995, 274:137-142.
19. Henrich JB: The postmenopausal estrogen/breast cancer controvesy. JAMA 1992, 268:1900-1902.
20. Studd JWW: Hormone replacement therapy and breast cancer [Letter]. Lancet 1989, II:1164.
21. Natchtigall MJ, Smillen SW, Nachtigall RD, Nachtigall RH, Nachtigall LE: Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol 1992, 80:827-830.
22. Henderson BE, Paganini-Hill A, Ross RK: Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991, 1551:75-78.
23. Hunt K, Vessey M, McPherson K: Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynecol 1990, 97:1080-1086.
24. Criqui MH, Suarez L, Barrett-Connor E, McPhillips JW, Garbard C: Postmenopausal estrogen use and mortality. Am J Epidemiology 1988, 128:606-614.
25. Bergkvist L, Adami H-G, Persson I, Bergstrom R, Krusemo UB: Prognosis after breast cancer diagnosis in women exposed to estrogen-progestogen replacement therapy. Am J Epidemiology 1989, 130:221-228.
26. Strickland DM, Gambrell RD, Butzin CA, Strickland K: The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol 1992, 80:400-404.
27. Squitieri R, Tartter PI, Ahmed S, Brower ST, Theise ND: Carcinoma of the breast in postmenopausal hormone user and non-user controls. J Am Coll Surg 1994, 178:167-170.
28. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L: • Clinical and biological prognostic factors in breast cancer diagnised during postmenopausal hormone replacement therapy. Obstet Gynecol 1995, 85:11-17. An interesting study raising the profile of the effect of E/HRT on tumour biology and tumour-host relationship.
29. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L: The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and supresses tumour growth. Nature 1994, 368:237-239.
30. Dupont WD: Influence of exogenous oestrogens, proliferative breast disease and other varaibles on breast cancer risk. Cancer 1989, 63:948-957.
31. Ewertz M: Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988, 42:832-838.
32. Persson I, Yuen J, Bergkvist L, Adami H-O, Hoover R, Schairer C: Combined oastrogen-progestogen replacement and breast cancer risk [Letter]. Lancet 1992, 340:1044.
33. Neven P, Shepherd JH, Lowe DG: Tamoxifen and the gynaecologist. Br J Obstet Gynaecol 1993, 100:893-897.
34. Sands RH, Boshoff C, Jones A, Studd JWW: Current Opinion: • hormone replacement therapy after a diagnosis of breast cancer. Menopause 1995, 2:73-80. A useful review of the studies where E/HRT has been administered to women with a history of breast cancer.
35. Stoll BA, Parbhoo S: Treatment of menopausal symptoms in breast cancer patients. Lancet 1988, I:1278-1279.
36. DiSaia PJ: Hormone replacement therpay in patients with breast cancer. Cancer Suppl 1993, 71:1490-1500.
37. Powles TJ, Hickish T, Casey S, O'Brian M: Hormone replacment therapy after breast cancer. Lancet 1993, 341:60-61.
38. Wile AG, Opfell RW, Margileth DA: Hormone replacement in previously treated breast cancer patients. Am J Surg 1993, 165:372-375.
39. Eden JA, Bush T, Nand S, Wren BG: A case-controlled study of •• combined continuous oestrogen-progestogen replacement therapy amongst women with a personal history of breast cancer. Menopause 1995, 2:67-72. The largest case-controlled study in which E/HRT was used for the treatment of menopausal symptoms after the diagnosis of breast cancer. The authors suggest that the short-term prescription of E/HRT does not affect prognosis adversely.
40. Dhadapkar MV, Ingle JN, Ahmann DL: Estrogen replacement therapy withdrawal and regression of metastatic breast cancer. Cancer 1995, 75:43-46.
41. Stoll BA: Effect of Lyndiol, an oral contraceptive, on breast cancer. Br Med J 1967, 1:150-153.